China-based iRegene Therapeutics has completed Series B+ financing exceeding RMB 300 million (USD 42 million) led by Northern Light Venture Capital and Chuangjing Capital, marking the largest investment in China's induced pluripotent stem cell (iPSC) sector. The funds will advance clinical development of NouvNeu001 for Parkinson's disease, which received Fast Track designation in the US in August 2025 following promising Phase I data showing sustained dopaminergic cell survival without immunosuppression.

NouvNeu001 is the first iPSC-derived universal dopamine precursor therapy to enter Phase II trials globally, demonstrating significant motor function improvement on UPDRS-III scales in early studies. iRegene's pipeline also includes NouvNeu003 for early-onset Parkinson's and NouvSight001 for retinal degeneration, with orphan drug designation (ODD) granted for the latter. The company's chemical induction platform enables cost-effective manufacturing of off-the-shelf cell therapies positioning it to compete with BlueRock Therapeutics' embryonic stem cell-based approaches.

PharmCube's MedAlpha® database shows that this is Northern Light's fifth investment in the industry this year alone, totalling 29 events since 2020. Click here to request a free trial for MedAlpha®.